✦ LIBER ✦

Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity

✍ Scribed by Casado, J. L.; Banon, S.; Rodriguez, M. A.; Santiuste, C.; Perez-Elias, M. J.; Moreno, A.; Moreno, S.

Book ID: 126660555
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 127 KB
Volume: 70
Category: Article
ISSN: 0305-7453
DOI: 10.1093/jac/dku402

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final 192-week efficacy and safety of on

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

✍ Orkin, C; DeJesus, E; Khanlou, H; Stoehr, A; Supparatpinyo, K; Lathouwers, E; Le 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB

Safety, Efficacy and Pharmacokinetics of

Safety, Efficacy and Pharmacokinetics of Ritonavir 400mg/Saquinavir 400mg Twice Daily plus Rifampicin Combined Therapy in HIV Patients with Tuberculosis

✍ Dr Valeria Cavalcanti Rolla, Maria A da Silva Vieira, Douglas Pereira Pinto, Mar 📂 Article 📅 2006 🏛 Springer International Publishing AG 🌐 English ⚖ 131 KB

Efficacy and safety of once daily elvite

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clote 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 209 KB

Long-Term (120-Week) antiviral efficacy

Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study

✍ Joseph C. Gathe Jr; Robin Wood; Ian Sanne; Edwin Dejesus; Schürmann Dirk; Andrze 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 544 KB

Once-daily atazanavir/ritonavir versus t

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

✍ Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetcho 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 246 KB